医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kemwell BioPharma wins “Best Contract Manufacturing Organization” at BioPharma Asia Industry Awards

2015年03月30日 PM10:50
このエントリーをはてなブックマークに追加


 

BANGALORE, India

Kemwell, a 100% CDMO providing customized process/ product development and manufacturing to pharmaceutical and biopharmaceutical organizations was honored as “Best Contract Manufacturing Organization” in Asia.

Kemwell was shortlisted after a rigorous round of nominations by industry thought leaders. SAFC, Lonza and Patheon were the other finalists in this category. “On behalf of the hundreds of voters who made their voices heard in the competition, we are pleased to present the Best Contract Manufacturing Organization Award to Kemwell BioPharma,” said Sharon Roessen, Managing Director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2015. “Kemwell’s work in India and its passion to continuously contribute to the biopharmaceutical industry is commendable.”

On receipt of this award, Sid Advant, President, Kemwell Biopharma – Biologics, commented, “We are proud to have been voted as the winner in this award category as it is a testament to our people, our work and our facilities. I would especially like to thank our customers and those who believed in us and took the time to vote for us. I congratulate my team for their dedication and commitment in making us a high-quality services provider. As a pure-play CDMO who has been around for 30+ years, we understand the importance of quality, cost, project timelines and responsiveness.”

Kemwell’s Greenfield state-of-the-art biologics facility (160,000 sq. ft.) in Bangalore, India has been built to produce highest quality biologics at cost effective prices. Kemwell provides an integrated development and manufacturing facility allowing clients to start with cell-bank generation and end with drug product manufacturing, all at one site.

At DCAT last week, Kemwell was also honored with multiple awards at the CMO Leadership Awards. They won awards in three categories: Innovation, Productivity and Regulatory. The CMO Leadership awards are based on industry research conducted by Nice Insight, a marketing research and intelligence agency. They chose the top 10% in each of these categories as winners.

Kemwell will be attending IBC’s Biopharmaceutical Development & Production Week Conference, in Huntington Beach, CA and Dr. Jaby Jacob, Asst. VP, Kemwell (Biologics Division) will give an oral presentation on “Meeting Diverse Technology Transfer Expectations – A CMO Perspective” on April 2nd at 8:45am. He will be using his 15+ years of biopharmaceutical experience to decode common technology transfer challenges. He will be presenting a case-study to discuss topics such as adaption of production processes to account for specific differences between equipment, facilities and process scale-up etc.

About Kemwell:

Kemwell Biopharma is a 100% CDMO that provides customized product development and cGMP compliant manufacturing solutions to pharmaceutical and biopharmaceutical organizations worldwide. With integrated facilities in India, US and Sweden, Kemwell delivers a comprehensive portfolio of services for sterile and non-sterile products from preformulation to commercial supply. Kemwell facilities are approved by USFDA, EMA, HC and PMDA.

Kemwell services over 100 global bio/ pharmaceutical companies, including 7 of the top 10 Big Pharma. Founded in 1980, Kemwell employs 1200 people, has 10 facilities worldwide and supplies to 80 countries globally.

Read more about Kemwell on www.kemwellbiopharma.com.

CONTACT

Kemwell BioPharma
Karan Bagaria, +91-80-39285450
VP
Corporate Development
karan.bagaria@kemwellpharma.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent